Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery

This study has suspended participant recruitment.
(Protocol changes underway.)
Sponsor:
Information provided by:
Queen's University
ClinicalTrials.gov Identifier:
NCT00335231
First received: June 8, 2006
Last updated: May 17, 2007
Last verified: May 2006

June 8, 2006
May 17, 2007
June 2006
Not Provided
Difference in bacterial colony forming units (CFUs) between treatment (gatifloxacin) and no treatment group
Same as current
Complete list of historical versions of study NCT00335231 on ClinicalTrials.gov Archive Site
  • Bacterial sensitivity
  • Patient comfort
Same as current
Not Provided
Not Provided
 
Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery
The Effect of Preoperative Topical Gatifloxacin on Anterior Chamber Sample Cultures After Cataract Surgery.

Postoperative endophthalmitis, a possible severe complication of cataract surgery, is an infection of the anterior chamber of the eye caused by bacterial contamination and colonization through surgical incisions. Bacteria are thought to originate mainly from the patient’s skin and studies show that bacteria are commonly found in the anterior chamber following surgery. However, innate immune defences are usually able to control and eliminate bacterial growth before postoperative endophthalmitis occurs. Also, due to the low incidence of postoperative endophthalmitis, it is difficult to accurately evaluate preventative methods. This study will examine the efficacy of topical preoperative administration of gatifloxacin (a new fourth generation fluoroquinolone antibiotic) on reduction of bacterial contamination of the anterior chamber following cataract surgery. If the antibiotic is shown to lower bacteria count in cultures from anterior chamber fluid, it has the potential to lower the incidence of postoperative endophthalmitis.

Patients undergoing cataract surgery will be notified and asked to participate in the study by the physician in advance of the surgery, provided they do not possess any exclusion criteria. The participants will be randomly split into two groups; one group will receive topical application of gatifloxacin prior to surgery, while the other group will receive no eye drops. During surgery, a small sample of anterior chamber fluid will be removed from the eye and cultured in both broth and enrichment media for all subjects. Bacterial growth, i.e., colony forming units (CFUs), will be used as an indicator of the bacterial contamination of the fluid.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Endophthalmitis
Drug: gatifloxacin ophthalmic (ZYMAR)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
30
May 2007
Not Provided

Inclusion Criteria:

  • Cataract surgery on first eye (i.e., first cataract surgery.

Exclusion Criteria:

  • uveitis,
  • herpetic eye disease,
  • corneal ulceration,
  • severe blepharitis,
  • past trauma to the eye,
  • complicated cataract surgery (e.g., posterior capsule rupture),
  • previous intraocular surgeries.
Both
Not Provided
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00335231
QUEENS-SRE-3
Not Provided
Not Provided
Queen's University
Not Provided
Principal Investigator: Sherif El-Defrawy, MD PhD FRCSC Queen's University, Hotel Dieu Hospital, Kingston General Hospital
Queen's University
May 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP